GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35

Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roberto De Masi, Stefania Orlando
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	GANAB IFI35 neuroinflammation multiple sclerosis interferon Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/cf5ad9c582db4e58845a5c6cfa3c41cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf5ad9c582db4e58845a5c6cfa3c41cd
record_format	dspace
spelling	oai:doaj.org-article:cf5ad9c582db4e58845a5c6cfa3c41cd2021-11-25T18:40:07ZGANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI3510.3390/ph141111951424-8247https://doaj.org/article/cf5ad9c582db4e58845a5c6cfa3c41cd2021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1195https://doaj.org/toc/1424-8247Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (HCs) for the putative correlation of the densitometric expression of glucosidase II alpha subunit (GANAB) with clinical/paraclinical parameters and with interferon-induced protein 35 (IFI35). We also assessed the disease progression in terms of the Rio Score (RS) in order to distinguish the responder patients to IFN therapy (RS = 0) from the non-responder ones (RS ≥ 1). We found GANAB to be 2.51-fold downregulated in the IFN-treated group with respect to the untreated one (<i>p</i> < 0.0001) and 3.39-fold downregulated in responder patients compared to the non-responders (<i>p</i> < 0.0001). GANAB correlated directly with RS (r = 0.8088, <i>p</i> < 0.0001) and lesion load (LL) (r = 0.5824, <i>p</i> = 0.0014) in the IFN-treated group and inversely with disease duration (DD) (r = −0.6081, <i>p</i> = 0.0096) in the untreated one. Lower mean values were expressed for GANAB than IFI35 in IFN responder (<i>p</i> < 0.0001) and higher mean values in the non-responder patients (<i>p</i> = 0.0022). Inverse correlations were also expressed with IFI35 in the overall patient population (r = −0.6468, <i>p</i> < 0.0001). In conclusion, the modular expression of GANAB reflects IFI35, RS, DD, and LL values, making it a biomarker of neuroinflammation that is predictive for disease activity and treatment response in MS.Roberto De MasiStefania OrlandoMDPI AGarticleGANABIFI35neuroinflammationmultiple sclerosisinterferonMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1195, p 1195 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	GANAB IFI35 neuroinflammation multiple sclerosis interferon Medicine R Pharmacy and materia medica RS1-441
spellingShingle	GANAB IFI35 neuroinflammation multiple sclerosis interferon Medicine R Pharmacy and materia medica RS1-441 Roberto De Masi Stefania Orlando GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
description	Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (HCs) for the putative correlation of the densitometric expression of glucosidase II alpha subunit (GANAB) with clinical/paraclinical parameters and with interferon-induced protein 35 (IFI35). We also assessed the disease progression in terms of the Rio Score (RS) in order to distinguish the responder patients to IFN therapy (RS = 0) from the non-responder ones (RS ≥ 1). We found GANAB to be 2.51-fold downregulated in the IFN-treated group with respect to the untreated one (<i>p</i> < 0.0001) and 3.39-fold downregulated in responder patients compared to the non-responders (<i>p</i> < 0.0001). GANAB correlated directly with RS (r = 0.8088, <i>p</i> < 0.0001) and lesion load (LL) (r = 0.5824, <i>p</i> = 0.0014) in the IFN-treated group and inversely with disease duration (DD) (r = −0.6081, <i>p</i> = 0.0096) in the untreated one. Lower mean values were expressed for GANAB than IFI35 in IFN responder (<i>p</i> < 0.0001) and higher mean values in the non-responder patients (<i>p</i> = 0.0022). Inverse correlations were also expressed with IFI35 in the overall patient population (r = −0.6468, <i>p</i> < 0.0001). In conclusion, the modular expression of GANAB reflects IFI35, RS, DD, and LL values, making it a biomarker of neuroinflammation that is predictive for disease activity and treatment response in MS.
format	article
author	Roberto De Masi Stefania Orlando
author_facet	Roberto De Masi Stefania Orlando
author_sort	Roberto De Masi
title	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
title_short	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
title_full	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
title_fullStr	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
title_full_unstemmed	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
title_sort	ganab as a novel biomarker in multiple sclerosis: correlation with neuroinflammation and ifi35
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cf5ad9c582db4e58845a5c6cfa3c41cd
work_keys_str_mv	AT robertodemasi ganabasanovelbiomarkerinmultiplesclerosiscorrelationwithneuroinflammationandifi35 AT stefaniaorlando ganabasanovelbiomarkerinmultiplesclerosiscorrelationwithneuroinflammationandifi35
_version_	1718410863177629696

GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35

Ejemplares similares